Elizabeth Arden
This article was originally published in The Rose Sheet
Executive Summary
Unilever NV will offer approximately 2.3 mil. shares of Arden's common stock at $19.50 per share, company says June 9. Underwriters have a 30-day option to purchase an additional 231,793 shares of common stock to cover overallotments. Arden says it will receive no proceeds from the offering, but will use any net proceeds from exercise of the overallotment option to reduce borrowings under its $200 mil. revolving credit facility...
You may also be interested in...
Elizabeth Arden
Offering of nearly 2.6 mil. shares of common stock at $19.50 per share is complete, firm announces June 15. Unilever NV affiliates sold approximately 2.3 mil shares, and Arden sold 231,793 shares pursuant to an over-allotment option granted by the firm and exercised by the underwriter on June 10 (1"The Rose Sheet" June 14, 2004, In Brief). Shares sold comprise the remainder of common stock underlying firm's outstanding Series D Convertible Preferred stock. Since no shares of the Series D Convertible Preferred stock remain outstanding, Arden will not have to pay the 5% dividend on the outstanding liquidation and expects to incur a non-cash charge for the five-month period ending June 30 of approximately $19.2 mil. Charge will be the last associated with Series D Preferred Stock, company says...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.